Scientific Industries Earnings Call Transcripts
Fiscal Year 2025
-
Q3 2025 saw record revenue, driven by strong sales in bioprocessing and new AI-driven product features. The company completed the Genie division divestiture and is focused on expanding its DOTS and VIVID platforms, despite ongoing market caution and selective capital spending.
-
The company has transformed into a digital and AI-focused life science innovator, divesting legacy assets to invest in pharmacy automation and bioprocessing. With strong financials, a robust product roadmap, and major industry partnerships, it targets rapid growth and leadership in AI-enabled scientific tools.
-
Legacy Genie division sold, shifting focus to AI-driven life science and bioprocessing. Q2 revenue rose 66% sequentially but lagged year-over-year, with academic sales sharply down. R&D and commercial engagement remain strong despite industry headwinds.
-
The company is advancing digital automation in life science labs, launching new AI-enabled products and expanding its bioprocessing platform to reduce experiment costs and increase data output. With a strong financial position and major industry validation, it targets rapid growth and break-even by 2027.
-
Q1 2025 saw strong benchtop equipment sales and increased U.S. demand, but bioprocessing revenue declined due to funding delays and longer sales cycles. Despite macroeconomic headwinds, new financing, product launches, and a robust sales pipeline position the company for growth later in 2025.
Fiscal Year 2024
-
Fiscal 2024 saw operational streamlining, new product launches, and strong bioprocessing growth, with a 24% sales increase and a robust pipeline for 2025. The company reduced costs, improved margins, and is positioned for further expansion as industry conditions recover.
-
Sales rebounded in core and new product lines, with Vivid Pill Counter up 50% sequentially and bioprocessing U.S. revenue up 61% year-to-date. Cost reductions improved EBITDA and productivity, while new product launches and major account wins position the company for future growth.
-
Genie and Torbal product lines rebounded after industry disruptions, with rapid growth expected from the VIVID Workstation launch. Bioprocessing saw 16% sales growth and 20% EBITDA improvement in H1, driven by strong U.S. performance and cost savings, while the DOTS platform gained early industry endorsement.